1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
RBC Bioscience Corporation

RBC Bioscience Corporation

TTPEX:6848
20.80
TWD
-0.15
(-0.72%)
289.75MMarket Cap
RBC Bioscience Corporation
TPEX:6848
(Taipei Exchange)

Recent

price

20.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
15.13
18.58
47.22
19.31
12.18
12.08
14.38
- -
- -
Revenue per Share
- -
1.64
1.66
11.65
2.21
0.26
0.45
1.51
- -
- -
Basic EPS, GAAP
- -
-7.94
3.5
7.17
-36.54
-0.24
0.47
3.2
- -
- -
Free Cash Flow per Basic Share
- -
2.36
1.41
4.5
1.11
0.83
1.02
0.91
- -
- -
Dividend per Share
5.66
5.99
6.15
12.24
17.99
17.43
16.86
17.47
- -
18.22
Book Value per Share
5.32
5.69
5.87
11.99
17.77
17.26
16.64
16.56
- -
17.12
Tangible Book Value per Share
14
8
9
12
13
14
14
14
14
14
Basic Weighted Avg Shares
- -
126
162
575
251
174
172
205
- -
- -
Sales/Revenue/Turnover
- -
11.19
12.1
32.75
19.2
4.4
8.49
17.44
- -
- -
Operating Margin (%)
- -
6
10
14
20
20
19
18
- -
- -
Depreciation Expense
- -
14
14
142
29
4
6
22
- -
- -
Net Income, GAAP
- -
19.88
19.81
19.99
20.08
23.15
18.33
20.01
- -
- -
Effective Tax Rate (%)
- -
10.87
8.94
24.67
11.44
2.17
3.73
10.51
- -
- -
Profit Margin (%)
61
42
35
20
61
33
40
45
- -
10
Working Capital
- -
40
47
42
442
417
413
401
- -
340
LT Debt
81
86
88
175
257
249
241
249
- -
260
Total Equity
- -
10.55
9.9
51.94
6.36
0.76
1.59
3.87
- -
- -
Return on Invested Capital (%)
- -
12.78
9.66
49.36
5.63
1.23
1.97
4.1
- -
- -
Return on Capital (%)
- -
16.47
16.69
108.13
13.31
1.49
2.63
8.8
- -
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
82
- -
72
LT Borrowings
378
- -
340
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
239
241
290

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
150
- -
133
Cash, Cash Equivalents & STI
61
- -
43
Accounts Receivable, Net
28
- -
29
Inventories
50
- -
48
Total Current Liabilities
117
- -
123
Payables & Accruals
- -
- -
- -
ST Debt
82
- -
72
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
205
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.51
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.91
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
RBC Bioscience Corporation (6848.TWO) researches, develops, manufactures, and sells reagents and automated devices for life science research and molecular diagnostics; its core offerings include molecular biomedical diagnostic and research reagents, Real Genomics branded nucleic acid extraction kits, MagCore automated nucleic acid extraction systems such as MagCore EDA for DNA/RNA extraction combined with PCR setup, gene extraction reagent kits, automated testing instruments, HIT Competent cells for rapid transformation, OnePick Blunt End Cloning Vectors, and related automation solutions like spectrophotometers, HEPA-filtered systems, and LIMS-compatible workflows. Founded in 2003 and headquartered in New Taipei City, Taiwan, the ISO 9001-, CE-, and QMS-certified company operates globally with distributors in over 27 countries, including strong presences in Europe (Italy, Spain, Germany, Netherlands), Asia, and North America, targeting clinical diagnostics, forensics, research laboratories, and molecular biology applications. Recent developments encompass sustained dividend payments including a TWD 0.30 per share semi-annual payout declared in August 2025, ongoing innovation in automated extraction technologies following the 2022 MagCore EDA launch, and recapitalization efforts since 2006 to support international molecular diagnostic market expansion.